Literature DB >> 9021543

Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.

D Marais1, R C Rose, A L Williamson.   

Abstract

Sera from 95 women with cervical intraepithelial neoplasia (CIN), 95 age-matched female blood donors, and 155 children aged between 1 and 12 years were tested by enzyme-linked immunosorbent assay (ELISA) for levels of serum IgG to three human papillomavirus (HPV) peptides (HPV-16 E2 [E2-16], HPV-18 E2 (E2-18], HPV-16 L1 [L1-16]), as well as HPV-16 virus-like particles (VLP-16) and bovine papillomavirus type 1 virus-like particles (BPV-VLP). In the adult group antibodies to E2-16 and VLP-16 were significantly associated with CIN when compared to the blood donor controls (P = .039 and P = .002, respectively). In women with CIN there was an increase in seropositivity to E2-16 and a decrease in seropositivity to VLP-16 with age. Antibodies to HPV-16 E2 could therefore be an important marker of CIN in women over 40 years of age, whereas antibodies to VLP-16 could be a marker for CIN in younger women. There was no correlation with CIN and antibodies to E2-18, L1-16, and BPV-VLP. In the children's sera antibodies were detected to E2-16 (44.5%), E2-18 (18.7%), L1-16 (20%), VLP-16 (4.5%), and BPV-VLP (5.1%). Between the ages of 3 and 12 years the prevalence of antibodies to E2-16 decreased with age. The presence of antibodies to HPV-16 in young children indicated infection with either HPV-16 or a related virus. HPV DNA isolation from children could help resolve this question.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021543     DOI: 10.1002/(sici)1096-9071(199702)51:2<126::aid-jmv7>3.0.co;2-9

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.

Authors:  Jo-Ann S Passmore; Michelle Milner; Lynnette Denny; Candice Sampson; Dianne J Marais; Bruce Allan; Pam P Gumbi; Inga I Hitzeroth; Edward P Rybicki; Anna-Lise Williamson
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

3.  Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.

Authors:  Parinda A Mehta; Sharon Sauter; Xue Zhang; Stella M Davies; Suzanne I Wells; Kasiani C Myers; Gitika Panicker; Elizabeth R Unger; Melinda Butsch Kovacic
Journal:  Vaccine       Date:  2017-10-16       Impact factor: 3.641

4.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

5.  Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Authors:  Dianne J Marais; Debbie Constant; Bruce Allan; Henri Carrara; Margaret Hoffman; Samuel Shapiro; Chelsea Morroni; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

6.  Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.

Authors:  Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt
Journal:  BMC Infect Dis       Date:  2022-01-10       Impact factor: 3.090

7.  Seroprevalence of 34 human papillomavirus types in the German general population.

Authors:  Kristina M Michael; Tim Waterboer; Peter Sehr; Annette Rother; Ulrich Reidel; Heiner Boeing; Ignacio G Bravo; Jörg Schlehofer; Barbara C Gärtner; Michael Pawlita
Journal:  PLoS Pathog       Date:  2008-06-20       Impact factor: 6.823

8.  New Approaches to Immunotherapy for HPV Associated Cancers.

Authors:  Anne-Sophie Bergot; Andrew Kassianos; Ian H Frazer; Deepak Mittal
Journal:  Cancers (Basel)       Date:  2011-09-02       Impact factor: 6.639

9.  Validation of Serological Antibody Profiles Against Human Papillomavirus Type 16 Antigens as Markers for Early Detection of Cervical Cancer.

Authors:  Dolores Azucena Salazar-Piña; Adolfo Pedroza-Saavedra; Aurelio Cruz-Valdez; Eduardo Ortiz-Panozo; Minerva Maldonado-Gama; Lilia Chihu-Amparan; Angelica Nallelhy Rodriguez-Ocampo; Emilia Orozco-Fararoni; Fernando Esquivel-Guadarrama; Lourdes Gutierrez-Xicotencatl
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

10.  Serum Immune Profiling for Early Detection of Cervical Disease.

Authors:  Radwa Ewaisha; Gitika Panicker; Paul Maranian; Elizabeth R Unger; Karen S Anderson
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.